Merck to showcase 100+ oncology studies at 2026 ASCO meeting
Highlighting KEYTRUDA & expanding cancer pipeline
Highlighting KEYTRUDA & expanding cancer pipeline
Nearly one in five women worldwide are now living with obesity
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
We are building an AI-native operating system for pharma sales and distribution
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Subscribe To Our Newsletter & Stay Updated